U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249632) titled 'A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)' on Nov. 18.
Brief Summary: This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible subjects aged 12 to 80 years with a diagnosis of OMG (Myasthenia Gravis Foundation of America [MGFA] Clinical Classification Type I) will be randomized in a 1:1 ratio to receive either Telitacicept or a matching placebo. Subjects must be on a stable standard-of-care therapy and have an MG Impairment Index (PRO) oc...